Cladribine

克拉屈滨

Report date: 2026/04/10 20:01:49
NME

Base Information

Drug NameCladribine
Drug Alias Name2-Chlorodeoxyadenosine克拉曲滨克拉屈宾ChlorodeoxyadenosineLeustatine +[22] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionImmunosuppressants
TargetsRibonucleotide reductase
Therapy Area/IndicationsCNS Embryonal TumorNeutropeniaMyelodysplastic Syndromes +[16] 
Global Approved IndicationsNeutropeniaThrombocytopeniaAnemia +[6] 
Approved Indications in ChinaNeutropeniaThrombocytopeniaAnemia
Original Approved Country/TerritoryUnited States
Original Approved Date1993/02/26
Country/TerritoryCzechiaBelgiumBosnia and Herzegovina +[49] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesLipomedJohnson & Johnson
China Registration ClassN/A

Develop Information

Active CompaniesInstitute Of Psychiatry And Neurology, WarsawJohnson & Johnson Innovative MedicineMerck Healthcare Kgaa, Darmstadt, Germany, An Affiliate Of Merck Kgaa, Darmstadt, Germany +[12] 
Inactive CompaniesJanssen Pharmaceuticals IncNational Cancer InstituteThe University Of Texas MD Anderson Cancer Center +[5] 
Active IndicationsNeutropeniaMyelodysplastic SyndromesThrombocytopenia +[11] 
Inactive IndicationsCNS Embryonal TumorMultiple Sclerosis, Relapsing-RemittingCholangitis, Sclerosing +[5] 

Other Information

ATC CodeL01BB04L04AA40
Related LinksWikipediaDrugBankKEGG